Wall Street brokerages forecast that Evoke Pharma Inc (NASDAQ:EVOK) will report earnings of ($0.10) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Evoke Pharma’s earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.17). Evoke Pharma reported earnings of ($0.24) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 58.3%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, November 13th.
According to Zacks, analysts expect that Evoke Pharma will report full-year earnings of ($0.49) per share for the current financial year, with EPS estimates ranging from ($0.63) to ($0.40). For the next year, analysts anticipate that the company will report earnings of ($0.58) per share, with EPS estimates ranging from ($0.83) to ($0.33). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Thursday, August 9th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.02.
EVOK has been the topic of a number of recent research reports. ValuEngine upgraded shares of Evoke Pharma from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. HC Wainwright set a $9.00 price objective on Evoke Pharma and gave the stock a “buy” rating in a research report on Thursday, May 3rd. Finally, Zacks Investment Research upgraded Evoke Pharma from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Tuesday, May 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $7.83.
Shares of Evoke Pharma traded down $0.12, reaching $2.52, during mid-day trading on Friday, according to Marketbeat.com. The stock had a trading volume of 25,701 shares, compared to its average volume of 36,337. The firm has a market cap of $44.29 million, a P/E ratio of -3.04 and a beta of 1.46. Evoke Pharma has a 12 month low of $1.85 and a 12 month high of $4.09.
An institutional investor recently bought a new position in Evoke Pharma stock. Deutsche Bank AG acquired a new position in Evoke Pharma Inc (NASDAQ:EVOK) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 200,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $452,000. Deutsche Bank AG owned 1.30% of Evoke Pharma at the end of the most recent quarter. Institutional investors and hedge funds own 13.78% of the company’s stock.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
See Also: How do investors use RSI to grade stocks?
Get a free copy of the Zacks research report on Evoke Pharma (EVOK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.